Jetter Alexander, Kinzig Martina, Rodamer Michael, Tomalik-Scharte Dorota, Sörgel Fritz, Fuhr Uwe
Department of Pharmacology, Clinical Pharmacology, University Hospital Cologne, Köln, Germany.
Eur J Clin Pharmacol. 2009 Apr;65(4):411-7. doi: 10.1007/s00228-008-0597-0. Epub 2008 Dec 13.
Individual activities of N-acetyltransferase 2 (NAT2) and of xanthine oxidase (XO) can be assessed using ratios of urinary caffeine metabolites. We investigated how ratios changed over time and which urine collection interval would be the best for NAT2 and XO activity assessments.
On two occasions separated by 14 days, 16 healthy male Caucasians collected urine before and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16 and 16-24 h after a dose of 150 mg caffeine given in the framework of a phenotyping cocktail study. The metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine (1X), and 1-methylurate (1U) were quantified with LC-MS/MS. The molar ratio (AFMU + AAMU)/(1X + 1U + AFMU + AAMU) was used as a NAT2 metric, while the ratio 1U/(1X + 1U) served as XO metric.
The NAT2 ratios were stable in the intervals 4-24 h after caffeine dosing. Mean intra-individual coefficients of variation were 11-23% starting 4 h post-dose, while inter-individual variability reached 37-75%. The XO ratios increased gradually by 14% from the 2-4 to the 16-24 h interval. The mean intra- and inter-individual coefficients of variation of XO activity were 3-18 and 7-10% respectively. No significant differences between study occasions were observed.
Any sampling interval at least 4 h after caffeine dosing is suitable for NAT2 and XO activity assessments. XO activities can only be compared between volunteers and studies if the same urine collection schedule has been respected. The low intraindividual variability allows for sample sizes of 16 and 6 participants in crossover interaction studies of NAT2 and XO activity respectively.
可使用尿咖啡因代谢物比率评估N - 乙酰基转移酶2(NAT2)和黄嘌呤氧化酶(XO)的个体活性。我们研究了这些比率随时间如何变化,以及哪个尿液收集间隔最适合评估NAT2和XO活性。
在一项表型鸡尾酒研究框架下,16名健康的白种男性在相隔14天的两个时间点,服用150毫克咖啡因后,于服药前以及服药后0 - 2、2 - 4、4 - 6、6 - 8、8 - 12、12 - 16和16 - 24小时收集尿液。采用液相色谱 - 串联质谱法对代谢物5 - 乙酰氨基 - 6 - 甲酰氨基 - 3 - 甲基尿嘧啶(AFMU)、5 - 乙酰氨基 - 6 - 氨基 - 3 - 甲基尿嘧啶(AAMU)、1 - 甲基黄嘌呤(1X)和1 - 甲基尿酸(1U)进行定量。摩尔比(AFMU + AAMU)/(1X + 1U + AFMU + AAMU)用作NAT2指标,而比率1U/(1X + 1U)用作XO指标。
咖啡因给药后4 - 24小时内,NAT2比率稳定。给药后4小时起,个体内变异系数均值为11% - 23%,个体间变异达到37% - 75%。XO比率从2 - 4小时间隔到16 - 24小时间隔逐渐增加14%。XO活性的个体内和个体间变异系数均值分别为3% - 18%和7% - 10%。未观察到研究时间点之间的显著差异。
咖啡因给药后至少4小时的任何采样间隔均适用于NAT2和XO活性评估。只有在遵循相同尿液收集时间表的情况下,才能在志愿者和研究之间比较XO活性。个体内变异较低,在NAT2和XO活性的交叉相互作用研究中,分别允许16名和6名参与者的样本量。